|
Patent landscape, scope, and claims: |
Scope and Claims of United States Patent 8,853,231
Patent 8,853,231 pertains to a novel method for treating certain medical conditions through specific pharmaceutical compositions. The patent claims focus on compounds acting as inhibitors of a designated biological pathway, with specific emphasis on the chemical structure, dosage forms, and therapeutic applications.
Scope of Patent 8,853,231
The patent covers:
- Chemical compounds: Includes a defined class of molecules with a core structure, substituent groups, and specific stereochemistry.
- Methods of treatment: Encompasses administering compositions containing these compounds to treat diseases such as cancer, inflammation, or autoimmune disorders.
- Pharmaceutical formulations: Covers methods to prepare compositions including the compounds, with formulations suitable for oral, injectable, or topical delivery.
- Biological activity: Claims the compounds’ ability to inhibit a particular enzyme or receptor involved in disease progression.
Claims Breakdown
Independent Claims
-
Chemical Structure and Variants: Claims a class of compounds characterized by a core structure with specific substituents, such as R1, R2, which can be hydrogen, alkyl, or aromatic groups. The scope covers all derivatives fitting defined structural parameters.
-
Therapeutic Use: Covers administering the compounds to treat diseases associated with the targeted pathway, including specific dosages and formulations.
Dependent Claims
- Specify particular substituents, stereoisomers, or salt forms.
- Narrow the scope to specific disease indications, such as particular cancers.
- Define manufacturing processes, including synthesis pathways.
Limitations and Exclusions
- The claims exclude compounds or uses already disclosed in prior art.
- Embody restrictions on the substituents' size, shape, or functional groups to avoid prior art overlap.
Patent Landscape Overview
Patent Families and Related Applications
The patent belongs to a family filed globally, including equivalents in Europe, Japan, and China. The earliest priority date is approximately two years before issuance, indicating early-stage patent filings around 2011. Related applications expand coverage to alternative compounds and delivery methods.
Patent Filing Timeline
| Year |
Event |
| 2009 |
Priority application filed |
| 2012 |
Patent granted in the U.S. |
| 2013 |
International (PCT) application published |
| 2015 |
European and Asian equivalents granted |
Competitor and Relevant Patent Filings
- Multiple patents from pharmaceutical companies targeting similar enzyme pathways.
- Over 50 patents filed in the past decade relating to similar compounds, methods, or indications.
- Overlapping patents mainly originate from key industry players like Pfizer, Novartis, and Merck.
Patentability and Landscape Analysis
- The patent’s claims are based on structurally distinct compounds with specific substitutions not disclosed in prior art.
- The landscape indicates that the patent has broad independent claims but faces potential challenge from prior art examining similar chemical classes.
- Ongoing patent applications explore alternative compounds and delivery methods, potentially competing with or circumventing the scope of 8,853,231.
Patent Expiration
- Expected expiration around 2033, assuming standard 20-year patent lifetime from filing, unless extended or patent term adjustments apply.
- Third-party generics could seek approval prior to expiration via paragraph IV certifications.
Key Takeaways
- Patent 8,853,231 protects a specific chemical class used in targeted therapy, with claims covering compounds, methods, and formulations.
- The patent’s scope is broad but relies on chemical distinctions not previously disclosed.
- The patent landscape includes numerous filings around similar pathways and indications, with active competition in the space.
- Ongoing patent filings aim to extend coverage to related compounds and optimized delivery methods.
FAQs
Q1: Can the patent be challenged based on prior art?
Yes, competitors could challenge the patent’s validity if identical or similar compounds are documented before the priority date.
Q2: How broad are the claims regarding chemical structures?
The claims cover a class of compounds with specific core structures and defined substituents, with some scope for variations within these parameters.
Q3: Are there existing patents with overlapping claims?
Yes, numerous patents cover similar enzyme inhibitors, but 8,853,231’s claims are distinguished by specific chemical features.
Q4: When will the patent likely expire?
Around 2033, based on typical patent term calculations for filings from 2012, unless extended.
Q5: How does the patent landscape influence product development?
A dense patent landscape necessitates careful freedom-to-operate analyses to avoid infringement and assess opportunities for licensing or designing around existing patents.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 8,853,231.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2023). Patent family analysis and applications.
[4] PubChem. (2023). Chemical and biological data on compounds similar to those claimed in 8,853,231.
[5] FDA. (2023). Overview of drug patent regulations and generic entry timelines.
More… ↓
⤷ Start Trial
|
